Received by email:

File: 2018-06-26 News Release - Acquire balance of Marathon.pdf

                                  Kaneh Bosm BioTechnology Inc.
                                   810   789 West Pender Street
                                      Vancouver BC V6C 1H2
                                         Tel: 604.687.2308

                         NOT FOR DISSEMINATION IN THE UNITED STATES

                                           NEWS RELEASE


             KANEH BOSM BIOTECHNOLOGY CONSOLIDATES DISTRIBUTION CAPACITY
                           AFTER ADDING CULTIVATION ABILITY

VANCOUVER, British Columbia, June 26, 2018 - Kaneh Bosm BioTechnolgy Inc. (CSE:KBB) ("Kaneh
Bosm" or the "Company") has entered into a definitive agreement (the "Agreement") with
Marathon Global Inc. ("Marathon") to acquire the remaining 50% of Marathon that it does not
already own.

Marathon has an exclusive agreement with Cosmos Holdings Inc. ("Cosmos"), a European based
pharmaceutical distributor, to procure and distribute medical cannabis products and all cannabis
derivatives for clients of Cosmos in approved countries within its distribution network of 110 clients,
representing approximately 35,000 pharmacies in 16 countries.

This relationship brings an unparalleled ability to supply the overwhelming demand for cannabis and
cannabis extracts in Europe as Cosmos brings generations worth of experience and relationships to
Kaneh Bosm.

The company sees a unique marriage between its access to 35,000 pharmacies in Europe, Kaneh
Bosm's anticipated production from its recently announced acquisitions in Lesotho and Colombia,
Marathon's integrated Canadian LP suppliers, and its agreements on the ADM retail system which
already has several thousand units operating across Western Europe, many in retail pharmaceutical
settings.

The Company continues to further identify synergy internally to maximize the cross-pollination
between the Company's divisions.

Under the terms of the Agreement, the Company will pay $1-million and it will issue 15 million
shares. A finder's fee as per regulatory guidelines will also be payable on this transaction.



On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

"Michael Martinz"

Michael Martinz
President, Director
mmartinz@kanehbosmbiotech.com


THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR
ADEQUACY OF THIS RELEASE.
 This news release includes certain statements that may be deemed "forward-looking statements".
The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would",
"project", "should", "believe" and similar expressions are intended to identify forward-looking
statements. Although the Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance should not be placed on the
forward looking statements because the Company can give no assurance that they will prove to be
correct. Since forward-looking statements address future events and conditions, by their very nature
they involve inherent risks and uncertainties. These statements speak only as of the date of this
News Release. Actual results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in the Company's disclosure
documents which can be found under the Company's profile on www.sedar.com